摘要
经皮冠脉介入手术(PCI)已成为解除冠脉血管严重狭窄的主要非外科治疗方法,术后双联抗血小板药物的治疗可有效地预防各种血栓性并发症,减低心血管事件的发生及死亡率。近年来,在PCI后,阿司匹林及氯吡格雷的最佳维持剂量方面存在很多争议,本文就此问题结合大量国内外的研究及指南推荐进行综述,并对新型抗血小板药物的应用前景进行展望。
Percutaneous coronary intervention （PCI） is the main non-surgical method for releasing severe coronary stenosis. Postoperative dual antiplatelet drug therapy can effectively prevent the emergence of various thrombotic complications and reduce the occurrence of cardiovascular events and mortality. However, in recent years, there has been much controversy over the best maintenance dose of aspirin and clopidogrel after PCI. The article reviews large numbers of studies and guidelines both at home and abroad and discusses the application prospect of new antiplatelet agents.
出处
《心脏杂志》
CAS
2014年第5期614-617,共4页
Chinese Heart Journal
